|
1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2.
|
Tajima Y, Yamazaki K, Makino R, et al:
Gastric and intestinal phenotypic marker expression in early
differentiated-type tumors of the stomach: clinicopathologic
significance and genetic background. Clin Cancer Res. 12:6469–6479.
2006. View Article : Google Scholar
|
|
3.
|
Asavarut P, Zhao H, Gu J and Ma D: The
role of HMGB1 in inflammation-mediated organ injury. Acta
Anaesthesiol Taiwan. 51:28–33. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Nogueira-Machado JA and de Oliveira Volpe
CM: HMGB-1 as a target for inflammation controlling. Recent Pat
Endocr Metab Immune Drug Discov. 6:201–209. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Teiten MH, Gaigneaux A, Chateauvieux S, et
al: Identification of differentially expressed proteins in
curcumin-treated prostate cancer cell lines. OMICS. 16:289–300.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Chen J, Xi B, Zhao Y, et al: High-mobility
group protein B1 (HMGB1) is a novel biomarker for human ovarian
cancer. Gynecol Oncol. 126:109–117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kostova N, Zlateva S, Ugrinova I and
Pasheva E: The expression of HMGB1 protein and its receptor RAGE in
human malignant tumors. Mol Cell Biochem. 337:251–258. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Sterenczak KA, Joetzke AE, Willenbrock S,
et al: High-mobility group B1 (HMGB1) and receptor for advanced
glycation end-products (RAGE) expression in canine lymphoma.
Anticancer Res. 30:5043–5048. 2010.
|
|
9.
|
Choi J, Lee MK, Oh KH, et al: Interaction
effect between the receptor for advanced glycation end products
(RAGE) and high-mobility group box-1 (HMGB-1) for the migration of
a squamous cell carcinoma cell line. Tumori. 97:196–202.
2011.PubMed/NCBI
|
|
10.
|
Yao X, Zhao G, Yang H, et al:
Overexpression of high-mobility group box 1 correlates with tumor
progression and poor prognosis in human colorectal carcinoma. J
Cancer Res Clin Oncol. 136:677–684. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Liu Y, Xie C, Zhang X, et al: Elevated
expression of HMGB1 in squamous-cell carcinoma of the head and neck
and its clinical significance. Eur J Cancer. 46:3007–3015. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Tang CH, Keng YT and Liu JF: HMGB-1
induces cell motility and α5β1 integrin expression in human
chondrosarcoma cells. Cancer Lett. 322:98–106. 2012.
|
|
13.
|
Mardente S, Mari E, Consorti F, et al:
HMGB1 induces the overexpression of miR-222 and miR-221 and
increases growth and motility in papillary thyroid cancer cells.
Oncol Rep. 28:2285–2289. 2012.PubMed/NCBI
|
|
14.
|
Yan W, Chang Y, Liang X, et al: High
mobility group box 1 activates caspase-1 and promotes
hepatocellular carcinoma invasiveness and metastases. Hepatology.
55:1863–1875. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Lee H, Song M, Shin N, et al: Diagnostic
significance of serum HMGB1 in colorectal carcinomas. PLoS One.
7:e343182012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Liu L, Yang M, Kang R, et al:
HMGB1-induced autophagy promotes chemotherapy resistance in
leukemia cells. Leukemia. 25:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Yang L, Yu Y, Kang R, et al: Up-regulated
autophagy by endogenous high mobility group box-1 promotes
chemoresistance in leukemia cells. Leuk Lymphoma. 53:315–322. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Sterenczak KA, Kleinschmidt S, Wefstaedt
P, et al: Quantitative PCR and immunohistochemical analyses of
HMGB1 and RAGE expression in canine disseminated histiocytic
sarcoma (malignant histiocytosis). Anticancer Res. 31:1541–1548.
2011.
|
|
19.
|
Peng RQ, Wu XJ, Ding Y, et al:
Co-expression of nuclear and cytoplasmic HMGB1 is inversely
associated with infiltration of CD45RO+ T cells and
prognosis in patients with stage IIIB colon cancer. BMC Cancer.
10:4962010. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Jiao Y, Wang HC and Fan SJ: Growth
suppression and radiosensitivity increase by HMGB1 in breast
cancer. Acta Pharmacol Sin. 28:1957–1967. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Hanahan D and Weinberg RA: The hallmarks
of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Sun KK, Ji C, Li X, et al: Overexpression
of high mobility group protein B1 correlates with the proliferation
and metastasis of lung adenocarcinoma cells. Mol Med Rep.
7:1678–1682. 2013.PubMed/NCBI
|
|
23.
|
Wang W, Jiang H, Zhu H, et al:
Overexpression of high mobility group box 1 and 2 is associated
with the progression and angiogenesis of human bladder carcinoma.
Oncol Lett. 5:884–888. 2013.
|
|
24.
|
van Beijnum JR, Nowak-Sliwinska P, van den
Boezem E, et al: Tumor angiogenesis is enforced by autocrine
regulation of high-mobility group box 1. Oncogene. 32:363–374.
2013.PubMed/NCBI
|
|
25.
|
Wild CA, Brandau S, Lotfi R, et al: HMGB1
is overexpressed in tumor cells and promotes activity of regulatory
T cells in patients with head and neck cancer. Oral Oncol.
48:409–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Mao XJ, Wang GF, Chen ZJ, et al:
Expression of HMGB1 and its clinical significance in T-cell
lymphoma. Asian Pac J Cancer Prev. 13:5569–5571. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Dong YD, Cui L, Peng CH, et al: Expression
and clinical significance of HMGB1 in human liver cancer: knockdown
inhibits tumor growth and metastasis in vitro and in
vivo. Oncol Rep. 29:87–94. 2013.PubMed/NCBI
|
|
28.
|
Akaike H, Kono K, Sugai H, et al:
Expression of high mobility group box chromosomal protein-1
(HMGB-1) in gastric cancer. Anticancer Res. 27:449–457.
2007.PubMed/NCBI
|
|
29.
|
Kang R, Tang D, Schapiro NE, et al: The
HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by
regulating mitochondrial bioenergetics. Oncogene. Jan 14–2013.Epub
ahead of print. View Article : Google Scholar
|
|
30.
|
Liang X, Chavez AR, Schapiro NE, et al:
Ethyl pyruvate administration inhibits hepatic tumor growth. J
Leukoc Biol. 86:599–607. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Zhang J, Zhu JS, Zhou Z, et al: Inhibitory
effects of ethyl pyruvate administration on human gastric cancer
growth via regulation of the HMGB1-RAGE and Akt pathways in
vitro and in vivo. Oncol Rep. 27:1511–1519.
2012.PubMed/NCBI
|
|
32.
|
Weng H, Deng Y, Xie Y, et al: Expression
and significance of HMGB1, TLR4 and NF-κB p65 in human epidermal
tumors. BMC Cancer. 13:3112013.
|
|
33.
|
Czyzewska J, Guzińska-Ustymowicz K, Lebelt
A, et al: Evaluation of proliferating markers Ki-67, PCNA in
gastric cancers. Rocz Akad Med Bialymst. 49:64–66. 2004.PubMed/NCBI
|
|
34.
|
Cawston TE and Wilson AJ: Understanding
the role of tissue degrading enzymes and their inhibitors in
development and disease. Best Pract Res Clin Rheumatol.
20:983–1002. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Park SK, Hwang YS, Park KK, et al:
Kalopanaxsaponin A inhibits PMA-induced invasion by reducing matrix
metallo-proteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling
in MCF-7 human breast cancer cells. Carcinogenesis. 30:1225–1233.
2009. View Article : Google Scholar
|
